Compare Globus Medical Inc. Class A Common Stock (GMED) vs Kohl's Corporation (KSS) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Kohl's (KSS) trades at $21.15, down slightly by 0.09% on the day, with the stock showing bullish technical signals from moving averages. The company has beaten earnings expectations for three consecutive quarters, including a significant Q2 2026 beat of $1.28 EPS versus $0.58 expected. Despite declining revenues, Kohl's maintains attractive valuation metrics with a P/E of 9.06 and P/S of 0.16, while recent management changes and operational improvements provide potential catalysts.

The investment case centers on deep value metrics and operational turnaround potential, though persistent revenue declines and competitive pressures remain key risks. Analyst sentiment is mixed with 30% buy ratings but a consensus price target of $15.50 below current levels, suggesting cautious optimism about the company's ability to stabilize sales and improve profitability in a challenging retail environment.